Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HK262: sourced facts only. name: "Here, we report the identification of 6d as a METTL21A inhibitor and the subsequent structure-activity relationship (SAR) study of analogues decorated with various fluorinated substituents, leading to metabolically stable 6n (HK262) with an IC50 1.10 μM." [PMID:42623743]; target: "Here, we report the identification of 6d as a METTL21A inhibitor and the subsequent structure-activity relationship (SAR) study of analogues decorated with various fluorinated substituents, leading to metabolically stable 6n (HK262) with an IC50 1.10 μM." [PMID:42623743]; developer: "Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Prague, Czech Republic; Faculty of Chemical Technology, University of Chemistry and Technology, Prague, Czech Republic." [PMID:42623743]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on HK262.